Application of PSMA PET/CT and PET/MRI imaging in the diagnosis of prostate cancer

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500109332

Enrollment

Unknown

Registered

2025-09-16

Start date

2023-07-24

Completion date

Unknown

Last updated

2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Gold Standard:Diagnostic criteria for prostate cancer

Index test:PSMA PET/CT PET/MRI

Eligibility

Sex/Gender

Male

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Prostate cancer patients with suspected or confirmed PSMA positive were selected to detect the initial lesions and metastases before operation. Or prostate cancer patients who intend to receive PSMA targeted therapy.

Exclusion criteria

Exclusion criteria: 1. Patients with malignant tumors, severe infections, and severe trauma; Those who are known to be allergic to the test drug or related products; Those with a history of drug abuse and alcohol dependence; Those who have participated in other clinical trials within 3 months before inclusion. 2. Those who have a history of allergy to contrast agents or other drugs. 3. Pregnant women.

Design outcomes

Primary

Measure	Time frame
normalized uptake ratio;	—

Countries

China

Contacts

Public ContactWang Xinlu

The First Affiliated Hospital of Guangzhou Medical University

71Lu@163.com+86 132 2661 6001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026